INTRODUCTION: Tocilizumab (TCZ), a recombinant humanized antihuman monoclonal antibody targeting interleukin-6 (IL-6) signaling, is often utilized in the management of autoimmune disease. Few reports have demonstrated hair growth changes in patients on TCZ. CASE PRESENTATION: Herein, we review the literature and report a 21-year-old woman with progressive alopecia areata (AA) presenting with AA improvement while on TCZ for concomitant posterior uveitis. DISCUSSION: Our case demonstrates the potential ability of TCZ to disrupt IL-6 signaling involved in AA, leading to hair loss and regrowth.
INTRODUCTION: Tocilizumab (TCZ), a recombinant humanized antihuman monoclonal antibody targeting interleukin-6 (IL-6) signaling, is often utilized in the management of autoimmune disease. Few reports have demonstrated hair growth changes in patients on TCZ. CASE PRESENTATION: Herein, we review the literature and report a 21-year-old woman with progressive alopecia areata (AA) presenting with AA improvement while on TCZ for concomitant posterior uveitis. DISCUSSION: Our case demonstrates the potential ability of TCZ to disrupt IL-6 signaling involved in AA, leading to hair loss and regrowth.
Authors: Teresa Song; Ana B Pavel; Huei-Chi Wen; Kunal Malik; Yeriel Estrada; Juana Gonzalez; Peter W Hashim; John K Nia; Danielle Baum; Grace Kimmel; Giselle K Singer; James G Krueger; Emma Guttman-Yassky Journal: J Allergy Clin Immunol Date: 2018-07-05 Impact factor: 10.793
Authors: Luzhou Xing; Zhenpeng Dai; Ali Jabbari; Jane E Cerise; Claire A Higgins; Weijuan Gong; Annemieke de Jong; Sivan Harel; Gina M DeStefano; Lisa Rothman; Pallavi Singh; Lynn Petukhova; Julian Mackay-Wiggan; Angela M Christiano; Raphael Clynes Journal: Nat Med Date: 2014-08-17 Impact factor: 53.440
Authors: Victor L Perez; George N Papaliodis; David Chu; Fahd Anzaar; William Christen; C Stephen Foster Journal: Ocul Immunol Inflamm Date: 2004-09 Impact factor: 3.070
Authors: Katarzyna Tomaszewska; Magdalena Kozłowska; Andrzej Kaszuba; Aleksandra Lesiak; Joanna Narbutt; Anna Zalewska-Janowska Journal: Oxid Med Cell Longev Date: 2020-08-03 Impact factor: 6.543